pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$IMVTImmunovant, Inc.

$IMVT29.90+2.96%
Durham, NC, USupdated 16d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 1Phase 3: 1
1Phase 21Phase 3
Phase 3
imeroprubart
Rheumatoid Arthritis
Phase 2
batoclimab
Graves Diseases

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Immunovant, Inc. jobs →

News

  • Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
    Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infect…
    biospace · 29d ago
  • Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
    CEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.
    biospace · 1mo ago
  • 6 immunology targets to sustain a mammoth I&I market
    Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
    biospace · 1mo ago
  • Lilly’s latest China drug deal; Immunovant’s setback in lupus
    Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…
    biopharma_dive · 1mo ago
  • Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
    After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from the indication and looking to other high priority programs for the drug i…
    biospace · 1mo ago
  • Roivant reports Phase 2b lupus failure for an FcRn drug
    One of Roivant’s leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning. The program, known as IMVT-1402 or imeroprubart, did not impr…
    endpoints · 1mo ago
  • Immunovant ends cutaneous lupus program after phase 2 flop
    Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.
    fiercebiotech · 1mo ago
identifiers
ticker
$IMVT
SEC CIK
0001764013
country
US
source
sec_tickers
top tags
Immunology1Rheumatoid Arthritis1
mentioned in
7news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 11m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?